PrEP in The United Kingdom

PrEP is provided through publicly funded health services; delivery arrangements differ among the four UK nations. England reported 111,123 people accessing PrEP in 2024. [Source: https://www.gov.uk/government/statistics/hiv-annual-data/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2025-report] Lenacapavir for PrEP (Yeytuo) was approved by the MHRA in December 2025, but NICE draft guidance of 9 September 2026 does not recommend it for use in NHS England on cost-effectiveness grounds; the consultation closes on 30 September 2026 and the next committee meeting is scheduled for 3 November 2026. Injectable cabotegravir PrEP was recommended by NICE in October 2025 with a restricted indication for people who cannot use oral PrEP effectively. [Source: https://www.nice.org.uk/guidance/indevelopment/gid-ta11638]